Kineta, Inc. (KANT)
| Market Cap | 5.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.28M |
| Shares Out | 12.26M |
| EPS (ttm) | -1.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,816 |
| Open | 0.400 |
| Previous Close | 0.390 |
| Day's Range | 0.373 - 0.466 |
| 52-Week Range | 0.260 - 3.980 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 21, 2025 |
About Kineta
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with ad... [Read more]
Full Company ProfileFinancial Performance
In 2023, Kineta's revenue was $5.44 million, an increase of 178.65% compared to the previous year's $1.95 million. Losses were -$14.10 million, -77.76% less than in 2022.
Financial StatementsNews
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT
NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securiti...
KANT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kineta, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kineta, Inc. (OTC PINK: KANT) and TuHURA Biosciences, Inc. is fair to Kineta shareholde...
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end.
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer im...
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1
TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients wit...
Kineta, Inc Transitioning from Nasdaq to OTC Markets
Kineta will be trading under the symbol “KANT” on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right of firs...